v3.26.1
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2025
Mar. 12, 2026
Jun. 30, 2025
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2025    
Document Fiscal Year Focus 2025    
Document Fiscal Period Focus FY    
Entity Registrant Name Coya Therapeutics, Inc.    
Entity Central Index Key 0001835022    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Interactive Data Current Yes    
Current Fiscal Year End Date --12-31    
Entity Filer Category Non-accelerated Filer    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction Flag false    
Entity Well-known Seasoned Issuer No    
Entity Public Float     $ 89,422,016
Entity Shell Company false    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
Security12b Title Common Stock, par value $0.0001 per share    
Trading Symbol COYA    
Security Exchange Name NASDAQ    
Entity File Number 001-41583    
Entity Incorporation State Country Code DE    
Entity Tax Identification Number 85-4017781    
Entity Address Address Line1 5850 San Felipe St., Suite 500    
Entity Address City Or Town Houston    
Entity Address State Or Province TX    
Entity Address Postal Zip Code 77057    
City Area Code 800    
Local Phone Number 587-8170    
Document Annual Report true    
Document Transition Report false    
Documents Incorporated By Reference

DOCUMENTS INCORPORATED BY REFERENCE

 

None.

    
Auditor Firm ID 410    
Auditor Name Weaver and Tidwell, L.L.P.    
Auditor Location New York, NY    
Auditor Opinion

Opinion on the Financial Statements

 

We have audited the accompanying balance sheets of Coya Therapeutics, Inc as of December 31, 2025 and 2024, and the related statements of operations, stockholders’ equity and cash flows, for each of the two years in the period ended December 31, 2025 and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of Coya Therapeutics, Inc. (the Company) as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America

   
Entity Common Stock, Shares Outstanding   23,457,183